Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Trial Profile

Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms CAIRO2
  • Most Recent Events

    • 11 Oct 2016 Results (n=182) analysing copy number alterations as predictive biomarkers to bevacizumab response, presented at the 41st European Society for Medical Oncology Congress.
    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Results of the genome-wide association sub-study were presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top